Pharma Investing News

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease

Robert Lawrence — Wed, 24 Jun 2009 14:42:11 +0000

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the U.S.

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available For Relief Of Moderate To Severe Acute Pain

Robert Lawrence — Wed, 24 Jun 2009 10:00:00 +0000

Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA(TM) (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in patients 18 years of age or older is now available by prescription only in 50-mg, 75-mg and 100-mg tablets, announced PriCara,(R) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

HCPC Calls For Greater Healthcare Savings Through Improved Adherence To Prescription Drug Regimens

Robert Lawrence — Wed, 24 Jun 2009 10:00:00 +0000

With today’s announcement that the Pharmaceutical Research and Manufacturers of America (PhRMA) has offered to voluntarily grant some $80 billion in discounts to Medicare beneficiaries over the next decade in an effort to reduce overall healthcare costs, the Healthcare Compliance Packaging Council (HCPC) noted that far greater savings can be achieved if immediate steps are taken to help people take their prescription drugs properly.

New Vaccine From Intervet/Schering-Plough Animal Health Is First For Canine Influenza Virus

Robert Lawrence — Wed, 24 Jun 2009 10:00:00 +0000

Intervet/Schering-Plough Animal Health, the global leader in veterinary biologicals, announced the availability of the first vaccine against canine influenza virus (CIV), which was granted a conditional product license by the U.S. Department of Agriculture (USDA) on May 27, 2009, for use by veterinarians in the United States.

Also In Global Health News: Venezuela Voids Pharma Patents; Namibia Sanitation; Mapping Disease With Satellites; Zimbabwe Health Funding

Robert Lawrence — Tue, 23 Jun 2009 12:00:00 +0000

Venezuela To Void Some Pharmaceutical Patents Commerce Minister Eduardo Saman on Saturday said Venezuela plans to void some pharmaceutical patents and allow domestic manufacturers to produce licensed medicines, the AP/Buffalo News reports.

WorldCare Clinical Implements MCC’s Imaging Performance Metrics In Support Of Standardized Peformance For Imaging Trials

Robert Lawrence — Tue, 23 Jun 2009 11:00:00 +0000

45th DIA Annual Meeting — Booth # 1501 — WorldCare Clinical, LLC (WCC), a leading imaging CRO for clinical trials in the pharmaceutical, biotechnology and medical device industries, announced that it is offering version 1.0 of the Metrics Champion Consortium (MCC) Imaging Performance Metrics to all sponsors’ imaging trials beginning July 1, 2009, through its WorldPro™ technology solution.

Helix BioPharma To Present L-DOS47 Analytical Method Development Findings At 2009 AAPS National Biotechnology Conference

Robert Lawrence — Sat, 20 Jun 2009 07:00:00 +0000

Helix BioPharma Corp. (TSX, FSE: HBP) announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Association of Pharmaceutical Scientists (”AAPS”) National Biotechnology Conference, which runs from June 21st to 24th at the Washington State Convention and Trade Center in Seattle, Washington.

Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia

Robert Lawrence — Sat, 20 Jun 2009 07:00:00 +0000

Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone.

Lytix Biopharma And KAEL-GemVax Announce Joint Clinical Trial To Combine LTX-315 And GV1001 Cancer Immunotherapy

Robert Lawrence — Sat, 20 Jun 2009 07:00:00 +0000

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cancer. According to Lytix Biopharma CEO Gunnar Saelid and KAEL-GemVax CEO Jay Sangjae Kim, “We are delighted to announce this joint venture to test a combination of two very interesting experimental drugs.

BIO Commends Senate Committee On Small Business And Entrepreneurship’s SBIR Reauthorization

Robert Lawrence — Fri, 19 Jun 2009 14:00:00 +0000

Under legislation reported by the Senate Committee on Small Business and Entrepreneurship, small companies that receive the majority of their financing from venture capital will once again be considered eligible to compete for Small Business Innovation Research (SBIR) grants. The change will allow more small biotechnology start-ups to compete for these funds and continue critical research and development of medical advancements and breakthroughs.